Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VNDA?
Source: PRnewswire
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VNDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VNDA
Wall Street analysts forecast VNDA stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 6.790
Low
7.50
Averages
13.63
High
22.00
Current: 6.790
Low
7.50
Averages
13.63
High
22.00
About VNDA
Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors effective April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to significantly support Vanda's innovative pipeline.
- Strategic Development Opportunity: Dr. Duncan noted Vanda's history of innovation in CNS disorders positions the company well for upcoming product data releases, with impactful data anticipated over the next 12 months, potentially ushering in a new era of growth.
- Commitment to Value Creation: Dr. Duncan's appointment is viewed as a strategic investment in Vanda's mission to meet patient needs and create shareholder value, indicating the company's dedication to enhancing its market position and growth potential through its innovative product pipeline.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors on April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to provide valuable insights for Vanda's innovative pipeline.
- Strategic Growth Phase: Dr. Duncan noted that Vanda's history of innovation in CNS disorders and recent approvals of NEREUS™ and BYSANTI™ signify the company entering a new era of growth, with impactful data expected over the next 12 months to drive value creation.
- Commitment to Patient Needs: Dr. Duncan emphasized that his addition will help Vanda create broader stakeholder value while addressing patient needs, reflecting the company's confidence and commitment to future development.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
Vanda Pharmaceuticals Publishes Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals has published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical application that may enhance the company's reputation in the biopharmaceutical sector.
- BLA Submission: The company has submitted a Biologics License Application (BLA) for Imsidolimab to the FDA, with a target action date of December 12, 2026; approval could provide a new revenue stream and strengthen market competitiveness.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is expected to extend into the late 2030s, offering Vanda a long-term market advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only diversifies its product portfolio but also lays the groundwork for future market expansion.
See More
Vanda Pharmaceuticals Announces Imsidolimab Research Findings
- Research Publication: Vanda Pharmaceuticals published findings on the efficacy and safety of Imsidolimab for generalized pustular psoriasis in the New England Journal of Medicine, marking a significant advancement in clinical trials that is expected to enhance market recognition.
- BLA Submission: Vanda has submitted a Biologics License Application for Imsidolimab to the FDA, with a target action date of December 12, 2026, which could expedite the drug's market entry and address urgent patient needs.
- Patent Protection Extension: Regulatory and patent exclusivity for Imsidolimab is anticipated to extend into the late 2030s, providing Vanda with a long-term competitive advantage and ensuring its leadership in the treatment of rare diseases.
- Global Exclusive License: Vanda holds an exclusive global license for the development and commercialization of Imsidolimab, which not only enhances the diversity of its product portfolio but also lays a foundation for future revenue growth.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors effective April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to significantly support Vanda's innovative pipeline.
- Strategic Development Opportunity: Dr. Duncan noted Vanda's history of innovation in CNS disorders positions the company well for upcoming product data releases, with impactful data anticipated over the next 12 months, potentially ushering in a new era of growth.
- Commitment to Value Creation: Dr. Duncan's appointment is viewed as a strategic investment in Vanda's mission to meet patient needs and create shareholder value, indicating the company's dedication to enhancing its market position and growth potential through its innovative product pipeline.
See More
Vanda Pharmaceuticals Appoints New Board Member
- New Board Member: Vanda Pharmaceuticals appointed Dr. Charles Duncan to its Board of Directors on April 22, 2026, increasing the board to seven members, six of whom are independent, thereby enhancing corporate governance.
- Rich Industry Experience: Dr. Duncan brings nearly three decades of experience in biotechnology, having covered over 70 companies as a biotechnology analyst at Cantor Fitzgerald & Co., with a focus on neurology and psychiatry, which is expected to provide valuable insights for Vanda's innovative pipeline.
- Strategic Growth Phase: Dr. Duncan noted that Vanda's history of innovation in CNS disorders and recent approvals of NEREUS™ and BYSANTI™ signify the company entering a new era of growth, with impactful data expected over the next 12 months to drive value creation.
- Commitment to Patient Needs: Dr. Duncan emphasized that his addition will help Vanda create broader stakeholder value while addressing patient needs, reflecting the company's confidence and commitment to future development.
See More
ANAPTYS FINALIZES DIVESTITURE OF FIRST TRACKS BIOTHERAPEUTICS AND NOW FOCUSES SOLELY ON GSK AND VANDA FINANCIAL PARTNERSHIPS
Separation of First Tracks: ANAPTY has completed the separation of its first tracks in biotherapeutics.
Management of Financial Collaborations: The company now exclusively manages financial collaborations with GSK and Vanda.
See More
Vanda Pharmaceuticals Urges FDA to Withdraw Legislative Proposal
- Proposal Details: The FDA's FY 2027 Congressional Budget proposal seeks to eliminate the 180-day review requirement for new drug applications (NDAs), extending review timelines to 10-12 months, which could delay patient access to new medications.
- Vanda's Position: Vanda Pharmaceuticals argues that this change would exacerbate review delays, reduce transparency, and increase risks for small innovators, with CEO Mihael H. Polymeropoulos emphasizing that the FDA should comply with existing laws rather than seek to amend them to allow for slower reviews.
- Legal Context: Vanda highlights that federal courts have ruled the FDA's practice of exceeding the 180-day timeline as unlawful, and the agency currently takes up to two months just to decide whether to file an application, raising concerns about the proposal's implications.
- Industry Impact: The proposal could lead to longer wait times for patients to access new drugs and greater uncertainty for biotech innovators, prompting Vanda to urge FDA Commissioner Dr. Marty Makary to withdraw the provision and call on Congress to reject it.
See More
